6533b873fe1ef96bd12d4bb2

RESEARCH PRODUCT

Combination of bexarotene and rosuvastatin at sub-optimal doses impairs angiotensin ii-induced arterial mononuclear cell adhesion

Herminia González-navarroV. LopezMaría José SanzP. EscuderoLaura Piqueras

subject

BexaroteneChemistrymedicineRosuvastatinAdhesionPharmacologyCardiology and Cardiovascular MedicinePeripheral blood mononuclear cellAngiotensin IImedicine.drughttps://doi.org/10.1016/j.atherosclerosis.2014.05.201